Background: Excessive energy intake and obesity lead to the metabolic syndrome (MetS). Dietary saturated fatty acids (SFAs) may be particularly detrimental on insulin sensitivity (SI) and on other components of the MetS. Objective: This study determined the relative efficacy of reducing dietary SFA, by isoenergetic alteration of the quality and quantity of dietary fat, on risk factors associated with MetS. Design: A free-living, single-blinded dietary intervention study. Subjects and Methods: MetS subjects (n ¼ 417) from eight European countries completed the randomized dietary intervention study with four isoenergetic diets distinct in fat quantity and quality: high-SFA; high-monounsaturated fatty acids and two low-fat, high-complex carbohydrate (LFHCC) diets, supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) (1.2 g per day) or placebo for 12 weeks. SI estimated from an intravenous glucose tolerance test (IVGTT) was the primary outcome measure. Lipid and inflammatory markers associated with MetS were also determined. Results: In weight-stable subjects, reducing dietary SFA intake had no effect on SI, total and low-density lipoprotein cholesterol concentration, inflammation or blood pressure in the entire cohort. The LFHCC n-3 PUFA diet reduced plasma triacylglycerol (TAG) and non-esterified fatty acid concentrations (Po0.01), particularly in men. Conclusion: There was no effect of reducing SFA on SI in weight-stable obese MetS subjects. LC n-3 PUFA supplementation, in association with a low-fat diet, improved TAG-related MetS risk profiles.
Introduction
The prevalence of metabolic syndrome (MetS), affecting approximately 25% of the adult population, is set to rise further, given the exponential increase in obesity. 1 This in turn will lead to a greater incidence of type 2 diabetes mellitus and cardiovascular disease. [2] [3] [4] [5] Central obesity and insulin resistance are key causal components of the metabolic syndrome, 6 in combination with at least two other metabolic risk factors, such as raised plasma triacylglycerol (TAG), reduced high-density lipoprotein (HDL) cholesterol concentrations and hypertension. 7, 8 Studies suggest that diet and lifestyle interventions may be more effective in preventing the development of MetS than pharmacological agents. [9] [10] [11] Diet is not specifically identified as a risk factor for MetS. However, there is good evidence to suggest that metabolic stressors including energy-dense, high-fat diets promote obesity, insulin resistance and MetS. [12] [13] [14] [15] Total fat, particularly saturated fatty acids (SFAs), has been considered to promote insulin resistance and increase the risk of MetS. 16, 17 In overweight subjects, isoenergetic substitution of SFA for monounsaturated fatty acids (MUFAs) or carbohydrates impaired insulin sensitivity (SI). 18, 19 However, Vega-Lopez et al. did not demonstrate this result. 20 Studies in type 2 diabetics suggest that SFA promotes insulin resistance. 21, 22 However, the potential therapeutic effects of replacing SFA with MUFA or with a low-fat diet on insulin resistance in a large cohort of subjects with MetS are ill defined. Intervention studies have failed to show a consistent effect of longchain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) on insulin resistance. Earlier short-term, high-dose LC n-3 PUFA supplementation trials (3-6 g day À1 for 2-8 weeks) in subjects with impaired glucose tolerance improved SI. 23, 24 However, subsequent long-term, lower-dose LC n-3 PUFA trials (1.8-3.6 g day À1 for 2-6 months) failed to improve SI. [25] [26] [27] Nevertheless, LC n-3 PUFA has consistent TAGlowering effects, 28 which is an important component of MetS.
From a clinical perspective, it is difficult to define the optimum diet with which to treat MetS. It is unknown whether there is any metabolic advantage of adhering to low-SFA diets enriched in MUFA or to low-fat, high-complex carbohydrate (LFHCC) diets, and whether LC n-3 PUFA can attenuate the potential adverse effect of a low-fat, high-carbohydrate diet on TAG and HDL metabolism. LIPGENE was a pan-European, multicentre dietary intervention study designed to determine the relative efficacy of altering the quality and quantity of dietary fat on SI and metabolic risk factors associated with MetS. This was an isoenergetic intervention to exclude the effects of weight change. It represents the largest human dietary intervention study specifically designed to address this important public health issue within a pan-European cohort.
Subjects and methods

Study population and design
The LIPGENE human dietary intervention study was a randomized, controlled trial that complied with the 1983 Helsinki Declarations, and was approved by the local ethics committees of the eight intervention centres (Dublin, Ireland; Reading, UK; Oslo, Norway; Marseille, France; Maastricht, The Netherlands; Cordoba, Spain; Krakow, Poland; Uppsala, Sweden). Written informed consent was obtained from every participant, as approved by each institutional ethical committee. Free-living subjects with MetS, defined by a modified version of the NCEP ATP III criteria, 8 were included. Modifications to the definition included raising plasma glucose concentrations up to 7 mmol l À1 rather than to 6.1 mmol l
À1
, plasma TAG greater than 1.5 mmol l À1 rather than 1.7 mmol l À1 and treated hypertensive subjects. These modifications were made to aid in the recruitment process. Participants were characterized by at least three of the following parameters:
The study aimed to recruit 480 subjects (120 per diet group). The statistical power of the study design was based on SI as the primary outcome, with the ability to detect a physiologically relevant difference in SI (0.32 unit, s.d. ¼ 2) between diets at a significance level of 0.05 and a power of 0.8. 19 The resultant calculation (n ¼ 98) was increased (n ¼ 120 per group) to account for an anticipated 20% dropout rate. The LIPGENE trial profile is illustrated in Figure 1 . Inclusion and exclusion criteria are presented in Supplementary isoenergetic low-fat (28% energy), high-complex carbohydrate diet (8% SFA, 11% MUFA, 6% PUFA), with 1.24 g day À1 VLC n-3 PUFA supplement (LFHCC n-3).
The HSFA diet functioned as the control per reference diet, to reflect the fat content and composition of Northern Europe. 29 The intervention diets were specifically designed to reduce dietary SFA by replacement with MUFA or as part of an LFHCC diet, while keeping dietary energy and n-6 PUFA constant. Similar numbers of subjects were assigned to each diet within centres. Subjects adhered to the parallelgroup intervention diets for 12 weeks. Fat-modified food products produced by Unilever (Vlaardingen, The Netherlands) were provided to all participants to attain dietary fat targets in conjunction with their usual foods. The intervention strategy was described in detail previously. 29 Briefly, a novel food exchange model was used to achieve the dietary targets. Spreads, cooking oil, baking fats, mayonnaise and biscuits were produced with a specific fatty acid profile (either SFA or MUFA rich) to be used in the HSFA and HMUFA diet groups or low-fat spread and mayonnaise for the LFHCC groups. Volunteers were instructed to exchange any habitually used oils, fats or spreads with the study foods. Volunteers randomized to the HSFA diet were requested to consume only full-fat dairy foods and were asked to replace one snack product usually eaten with a study HSFA cookie daily. These volunteers were also advised to eat less carbohydrate. Volunteers randomized to diets HMUFA, LFHCC and LFHCC n-3 were requested to consume only low-fat dairy products. Volunteers on the HMUFA diet consumed HMUFA mayonnaise or a handful of hazelnuts or cashew nuts (naturally high in MUFA) and replaced one normally consumed snack product with their choice of HMUFA biscuit. In the LFHCC and LFHCC n-3 diets, volunteers reduced their intake of high-fat snacks, consumed Dietary fat and insulin sensitivityFLIPGENE AC Tierney et al two extra portions of complex carbohydrate daily and took the supplied capsules daily. The subjects were encouraged to use cooking oil and baking fat to prepare dishes in their home. Detailed dietetic counselling was given to the volunteers and frequent monitoring and dietary reinforcement maximized volunteer compliance. The intervention foods were delivered to each volunteer every 2 weeks by their dietitian. The LC n-3 PUFA supplement (Marinol C-38; 1.24 g per day LC n-3 PUFA) and placebo high-oleic acid sunflower seed oil supplement were supplied by Lipid Nutrition, Loders Croklaan (Wormerveer, The Netherlands). Written informed consent was attained before assessment of anthropometric indices, blood pressure, pregnancy and collection of a 12 h fasting blood sample. A health and lifestyle questionnaire determined each subject's habitual physical activity, smoking habits, alcohol intake, menopausal state and demographics; these did not change during the intervention. The trial was conducted in two phases, between February and July 2005 and between February and July 2006.
Dietary assessment and clinical investigations
A common training protocol and standard operating procedures were developed to standardize collection of biological samples and dietary data in each centre. A 3-day weighted food dietary record (two weekdays and one weekend day) assessed preintervention dietary habitual intake, used to design individualized isoenergetic dietary fat modification. 20 Two weighted 3-day food dietary records were completed mid-and postintervention at weeks 6 and 12 of the intervention period to assess compliance. 29 To avoid any confounding effect of weight loss, energy intake was adjusted if body weight changed 42 kg. Physical activity, alcohol consumption andr smoking habits were not altered.
Compliance was assessed by dietary assessment, capsule count and plasma fatty acid compositional analysis. Pre-and postintervention dietary composition is based on analysis of the 3-day weighted food records before and after intervention ( Table 1) . Following a 12 h overnight fast, anthropometric measurements were taken and a first void urine sample was donated. Body weight was measured using calibrated scales. Waist circumference was measured in duplicate directly on the skin, at the midpoint between the supra iliac crest and lower ribs margin at the end of a normal expiration, to the nearest 0.1 cm using a non-stretch tape measure. Hip circumference was measured in duplicate to the nearest 0.1 cm, using a non-restrictive tape measure, at the level of the greater trochanter without compressing the skin. Blood pressure measurements were recorded in duplicate in the seated position after a 5 min rest, using an appropriately sized cuff before blood samples were taken. Subjects then completed an insulin-modified intravenous glucose tolerance test before and after intervention. S I , glucose effectiveness and the acute insulin response to glucose were determined (MINMOD Millennium program version 6.02, Richard N. Bergman). 30 The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasting glucose (mg per 100 ml) multiplied by fasting insulin (mU ml À1 ) divided by 22.5.
Biochemical analysis
Blood samples for lipid, apolipoprotein (apo), glucose and inflammatory marker analyses were collected in potassium EDTA, fluoride oxalate and serum separator vacutainers. Samples, apart from serum, were centrifuged immediately (1500 g); plasma was aliquoted and stored at À80 1C. Standard methodologies were used to determine serum insulin and c-peptide (AutoDELFIA Insulin and AutoDELFIA C-Peptide kits; Wallac Oy, Turku, Finland). Plasma concentrations were monitored for total cholesterol, HDL-C, Table 1 Pre-and post-intervention dietary composition of subjects allocated to the four diet group in the LIPGENE Dietary Intervention Study Dietary fat and insulin sensitivityFLIPGENE AC Tierney et al low-density lipoprotein-C (LDL-C), TAG, non-esterified fatty acid (NEFA) and glucose (Instrumentation Laboratory, Warrington, UK; WAKO NEFA C kit, Alpha Laboratories, Hampshire, UK). HDL-C and LDL-C were precipitated (Randox CH1350 Laboratories Ltd, Co Antrim). TAG-rich lipoprotein (TRL) was isolated and stored (À20 1C) with an apoprotein preservative (5% v/v) as described. 31 Plasma apolipoproteins A-I, B and E were assayed by immunonephelometry (Behring Werke AG, Marburg, Germany), TRL apo B-48 levels by a competitive enzyme-linked immunosorbent assay and apo CIII and apo CII concentrations by immunoturbidimetric kits (Diasys, Bouffémont, France). Plasma fatty acids were extracted and transmethylated with borontrifluoride in methanol; composition was determined by gas liquid chromatography with a Shimadzu GC2010 (Shimadzu, Japan), as described in detail. 32 High-sensitivity 
Statistical analysis
All data are presented as group means ± standard error of the mean. Repeated measures ANOVA (RM-ANOVA) determined the effect of dietary fat modification on metabolic markers. As required, data were normalized by log, square root, inverse or sine transformation. Analyses were adjusted for between-subject factors: sex, centre and diet group with age and change of body weight as covariates. Significant timediet and time Â diet Â gender interactions and significant main effects were investigated using Bonferroni post hoc tests. A Bonferroni correction was applied for multiple testing. Post hoc analysis was completed to determine whether habitual fat intake, defined as being above or below the median preintervention fat intake (36% of total energy intake, excluding subjects with the lowest (5%) and highest (5%) total fat intake), influenced the metabolic response. All statistical analyses were performed using SPSS for Windows version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Dietary SFA modification did not alter insulin sensitivity, blood pressure or inflammation Dietary targets were largely achieved with significant isoenergetic reduction in dietary SFA, with replacement of MUFA or complex carbohydrates (Table 1) . Plasma fatty acid composition was determined as a biomarker of the dietary fatty acid intake. Plasma oleic acid showed significant diet Â time interaction (P ¼ 0.0005); levels increased following the HMUFA diet (P ¼ 0.033) and were lower after the HSFA and LFHCC n-3 diets (P ¼ 0.005) (Figure 2a ). Enrichment of plasma EPA and DHA levels followed the LFHCC n-3 diet (P ¼ 0.0005) (Figure 2b ). Plasma n-6 PUFA levels were not changed (data not shown), reflecting the intention not to alter dietary n-6 PUFA. The effects of dietary fat modification on markers of SI, blood pressure and anthropometric variables are presented in Table 2 . Age, body weight, blood pressure or insulin and glucose levels were not different between dietary groups before intervention. Reducing dietary SFA had no effect on SI, fasting insulin, glucose concentrations or HOMA-IR. Despite the isoenergetic intervention, a significant withinsubject time Â diet interaction (P ¼ 0.001) showed a small (o0.84 kg or 1% body weight) but significant reduction in body weight following the LFHCC and LFHCC n-3 diets; Dietary fat and insulin sensitivityFLIPGENE AC Tierney et al therefore, change in body weight was controlled for in all analyses. BMI, waist circumference and blood pressure were not significantly altered. Reducing dietary SFA had no effect on several biomarkers of inflammation, including plasma CRP, IL-6, TNFa, sICAM-1, sVCAM-1, resistin, adiponectin, leptin, PAI-1 and tPA concentrations (Table 3) .
LFHCC n-3 PUFA diet improved TAG and NEFA metabolism without an effect on cholesterol The effects of dietary fat modification on markers of lipid and lipoprotein metabolism are presented in Table 4 . Plasma TAG concentrations showed a significant diet Â time interaction (P ¼ 0.006), whereby plasma TAG concentrations were lower after the HSFA and LFHCC n-3 diets (P ¼ 0.018 and P ¼ 0.005, respectively). TRL TAG concentrations also showed a diet Â time interaction (P ¼ 0.049), with lower levels following the LFHCC n-3 diet only (P ¼ 0.032). Interestingly, TAG and TRL TAG showed a time Â gender Â diet interaction (P ¼ 0.017 and P ¼ 0.039, respectively). TAG and TRL TAG concentrations were reduced only in men after the HSFA and LFHCC n-3 diets (P ¼ 0.039 and P ¼ 0.002 (TAG), P ¼ 0.013 and P ¼ 0.008 (TRL TAG), respectively). Plasma NEFA concentrations showed a diet Â time interaction approaching significance (P ¼ 0.061); post hoc analysis showed lower NEFA levels following the LFHCC n-3 diet (P ¼ 0.006). Related to TAG metabolism, plasma apo CIII showed a significant time Â diet interaction (P ¼ 0.034); levels were reduced after the HSFA and LFHCC n-3 diets (P ¼ 0.014 and P ¼ 0.008, respectively). Neither plasma apo AI nor apo B, apo B48, TRL apo B, apo CII or apo E were significantly altered by dietary fat modification (data not shown). HDL cholesterol (HDLc), but not total plasma or LDL cholesterol, showed a diet Â time interaction (P ¼ 0.005). HDLc concentrations were increased after both high-fat diets, HSFA and HMUFA (Po0.0005 and P ¼ 0.006, respectively), which in turn improved the total to HDLc cholesterol ratio (P ¼ 0.005 diet Â time interaction). This ratio was also Abbreviations: HMUFA, high-monounsaturated fatty acids; HSFA, high-saturated fatty acid; LFHCC, low-fat, high complex carbohydrate. Values represent diet Â time adjusted means ( ± s.e.m.).
Dietary fat and insulin sensitivityFLIPGENE AC Tierney et al significantly improved after the LFHCC n-3 diet (Po0.005), mainly explained by lower total cholesterol levels.
Discussion
The LIPGENE Dietary Intervention Study is the largest panEuropean intervention study designed to determine the relative efficacy of reducing dietary SFA, by substitution with MUFA or as part of an isoenergetic LFHCC diet, in subjects with MetS. Contrary to our hypothesis that removal of dietary SFA might attenuate insulin resistance, isoenergetic reduction of SFA intake had no marked effect on SI in obese MetS subjects. Other risk factors of MetS were also unaltered by reducing SFA, including blood pressure, inflammation and LDL cholesterol. Dietary intervention target achievement 20 and altered plasma concentrations of oleic acid, EPA and DHA, biomarkers of dietary fat composition that also represent the dynamic flux between dietary and endogenous fatty acid supply, indicate compliance. The KANWU study showed that an HSFA diet reduced SI, and post hoc analysis indicated that reducing dietary SFA by replacement with MUFA may improve SI but only in subjects whose habitual preintervention dietary fat intake was below the median. 18 There are important differences between studies. First, weight-stable, obese (BMI 32.4±4.2 kg m
À2
) MetS subjects may be more metabolically inflexible or resistant to dietary SFA modification than slightly overweight (BMI 26.5± 3 kg m
) but otherwise healthy subjects, as studied in the KANWU study. Second, it is possible that greater or more prolonged modification of dietary SFA may be required to attenuate insulin resistance in subjects with MetS. As in the KANWU study, we completed exploratory post hoc analysis to unravel potential interactions between habitual fat intake, insulin resistance and SFA modification. Interestingly, in the LIPGENE study, HOMA-IR was significantly reduced in females with a habitual total fat intake below the median (36% of total energy), following the HMUFA diet (Figure 3 ). 
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Perhaps the impact of replacing SFA with MUFA on insulin resistance is dependent on preintervention fat intake. This may be explained by the greater increment in MUFA intake in habitual low-versus high-fat consumers ( þ 7.24±0.54% versus þ 2.87 ± 0.71%). Nevertheless, the exploratory nature of this post hoc analysis that shows potential effects on HOMA-IR as a marker of insulin resistance needs to be highlighted. It is beyond the scope of this study to determine the apparent habitual dietary fat and gender-specific nature of this observation. The potential hypertriacylglycerolemic effect of an LFHCC diet was ameliorated by LC n-3 PUFA supplementation, promoting reduced TAG and NEFA levels in men. Mechanisms include lower hepatic NEFA and TAG synthesis, attenuated very low-density lipoprotein (VLDL) production and increased plasma TAG clearance. 28, 32 Lower apo CIII levels would facilitate TRL catabolism and apo E-dependent hepatic uptake of TRL remnants. 33, 34 In men, very lowdensity lipoprotein (VLDL) TAG residence time is prolonged; thus, LC n-3 PUFA may have a greater effect on secretion and clearance. 35, 36 In addition, greater metabolic utilization of VLC n-3 PUFA has been demonstrated in men. 37 Unexpectedly, the HSFA diet reduced plasma TAG and apo CIII concentrations. It is important to note that this dietary group had higher, albeit not significant, preintervention TAG and apo CIII concentrations. Thus, it is possible that the reduction from higher initial levels represents regression towards the mean, wherein lower plasma apo CIII concentrations facilitated TAG clearance. The atherogenic index was reduced following the LFHCC n-3 PUFA diet, suggesting that the combined LFHCC and LFHCC n-3 PUFA diet protects against the adverse effect of low-fat diets alone, which often raise TAG and lower HDLc concentrations. HDLc concentrations were higher following the high-fat diets, reflecting the well-characterized impact of total fat on HDL metabolism. This increase in HDL in turn contributed to the lower total cholesterol:HDLc ratio following the HSFA and HMUFA diets. Total and LDL cholesterol concentrations did not show a significant diet Â time interaction, although dietary targets to reduce SFA intake were achieved. The LFHCC n-3 PUFA diet lowered LDL cholesterol by 7% (À0.23 mmol l À1 ), albeit nonsignificantly, which in turn contributed to a significant reduction in the total cholesterol: HDLc ratio, which reflected lower total cholesterol concentrations. Nevertheless, the reduction in LDLc is modest compared with other dietary low-SFA intervention studies. 18, 19, 38 However, Lefevre et al., demonstrated that individual variability in cholesterol responses to low-SFA diets is profoundly affected by BMI, adiposity and insulin. 39 It was shown that the reduction in LDL cholesterol was substantially less (30-42%) in subjects with BMI 425.3 and insulin concentrations 46.8 mU ml
À1
. Given the similar BMI and insulin-resistant profile of our cohort, we determined and identified a potential confounding effect of body weight, wherein LDL cholesterol was reduced more in overweight than in obese MetS subjects (À11.9% (À0.41 mmol l À1 ) versus À3.1% (À0.1 mmol l À1 ). Hence, as Lefevre et al. 39 concluded, weight loss may be required to fully derive the benefit of low-SFA, LDL cholesterol-lowering diets. The LIPGENE intervention study showed no significant effect of dietary fat modification on several markers of inflammation, coagulation, lipid peroxidation and oxidative stress. 40 It is difficult to modify the inflammatory phenotype by dietary fat modification alone, particularly in weightstable individuals. A recent study showed that LC n-3 PUFA supplementation (1.8 g day
) reduced PAI-1 levels, but not leptin, adiponectin, IL-6 or TNFa. 27 However, there are several others that have shown little effect. In summary, MetS is a heterogeneous condition requiring targeted dietary therapies for its different metabolic features. LC n-3 PUFA supplementation effectively reduced TAG and NEFA in men with MetS. Overall reduction of dietary SFA had no effect on SI, blood pressure, LDL cholesterol concentrations and markers of inflammation. Our study indicated that the preintervention dietary environment may modify responsiveness to dietary fat modification with respect to SI. However, a confirmation of this hypothesis would require a study designed specifically to address this issue. More extensive dietary fat modification may be required to significantly improve SI and other risk factors associated with MetS, perhaps in combination with weight loss. Although our study was designed with the weight-stable phenotype, potential interactions per synergism between dietary fat modification and weight loss need to be clarified. LIPGENE was specifically designed to address the impact of fat modification in a European population. This may have Dietary fat and insulin sensitivityFLIPGENE AC Tierney et al led to greater dietary and genetic heterogeneity between subjects owing to the multicentre nature of this study. To this end, work that focusses on the genetic aspect of responsiveness is ongoing.
